Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Cancer Sci

Retrieve available abstracts of 52 articles:
HTML format
Text format



Single Articles


    May 2017
  1. TANIGUCHI H, Yamada T, Takeuchi S, Arai S, et al
    The impact of MET inhibition on small-cell lung cancer cells exhibiting aberrant activation of the HGF/MET pathway.
    Cancer Sci. 2017 May 5. doi: 10.1111/cas.13268.
    PubMed     Text format     Abstract available


    April 2017
  2. WANG R, Deng X, Yoshioka Y, Vougiouklakis T, et al
    Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small cell lung cancer cells.
    Cancer Sci. 2017 Apr 1. doi: 10.1111/cas.13245.
    PubMed     Text format     Abstract available


    March 2017
  3. TODE N, Kikuchi T, Sakakibara T, Hirano T, et al
    Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.
    Cancer Sci. 2017 Mar 13. doi: 10.1111/cas.13233.
    PubMed     Text format     Abstract available


  4. HIDA T, Nishio M, Nogami N, Ohe Y, et al
    Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
    Cancer Sci. 2017 Mar 7. doi: 10.1111/cas.13225.
    PubMed     Text format     Abstract available


  5. SATO T, Shiba-Ishii A, Kim Y, Dai T, et al
    miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.
    Cancer Sci. 2017;108:536-542.
    PubMed     Text format     Abstract available


  6. KUSUMOTO H, Shintani Y, Kanzaki R, Kawamura T, et al
    Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.
    Cancer Sci. 2017;108:528-535.
    PubMed     Text format     Abstract available


    February 2017
  7. KAKUMU T, Sato M, Goto D, Kato T, et al
    Identification of Proteasomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer.
    Cancer Sci. 2017 Feb 6. doi: 10.1111/cas.13185.
    PubMed     Text format     Abstract available


  8. KAMIOKA Y, Takakura K, Sumiyama K, Matsuda M, et al
    Intravital Forster resonance energy transfer imaging reveals osteopontin-mediated polymorphonuclear leukocyte activation by tumor cell emboli.
    Cancer Sci. 2017;108:226-235.
    PubMed     Text format     Abstract available


  9. KARASAKI T, Nagayama K, Kuwano H, Nitadori JI, et al
    Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
    Cancer Sci. 2017;108:170-177.
    PubMed     Text format     Abstract available


    January 2017
  10. PARK JH, Inoue H, Kato T, Zewde M, et al
    TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
    Cancer Sci. 2017 Jan 11. doi: 10.1111/cas.13160.
    PubMed     Text format     Abstract available


  11. HARADA A, Uchino J, Harada T, Nakagaki N, et al
    Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
    Cancer Sci. 2017;108:116-123.
    PubMed     Text format     Abstract available


  12. IKEMURA S, Aramaki N, Fujii S, Kirita K, et al
    Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma.
    Cancer Sci. 2017;108:136-142.
    PubMed     Text format     Abstract available


    December 2016
  13. CHEN Y, Yang J, Li X, Hao D, et al
    First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Cancer Sci. 2016;107:1800-1805.
    PubMed     Text format     Abstract available


    November 2016
  14. HIBI M, Kaneda H, Tanizaki J, Sakai K, et al
    FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Cancer Sci. 2016;107:1667-1676.
    PubMed     Text format     Abstract available


  15. HIDA T, Nakagawa K, Seto T, Satouchi M, et al
    Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
    Cancer Sci. 2016;107:1642-1646.
    PubMed     Text format     Abstract available


    October 2016
  16. TANIGUCHI H, Takeuchi S, Fukuda K, Nakagawa T, et al
    AREG triggered EGFR activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by EGFR inhibitors.
    Cancer Sci. 2016 Oct 26. doi: 10.1111/cas.13111.
    PubMed     Text format     Abstract available


  17. GOTO K, Endo M, Kusumoto M, Yamamoto N, et al
    Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
    Cancer Sci. 2016 Oct 6. doi: 10.1111/cas.13096.
    PubMed     Text format     Abstract available


  18. KATO S, Yokoyama S, Hayakawa Y, Li L, et al
    P38 pathway as a key downstream signal of connective tissue growth factor to regulate metastatic potential in non-small-cell lung cancer.
    Cancer Sci. 2016;107:1416-1421.
    PubMed     Text format     Abstract available


  19. ITO T, Matsubara D, Tanaka I, Makiya K, et al
    Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
    Cancer Sci. 2016;107:1527-1538.
    PubMed     Text format     Abstract available


    September 2016
  20. MIYAZAKI K, Oyanagi J, Sugino A, Sato H, et al
    Highly sensitive detection of invasive lung cancer cells by novel antibody against amino-terminal domain of laminin gamma2 chain.
    Cancer Sci. 2016 Sep 29. doi: 10.1111/cas.13089.
    PubMed     Text format     Abstract available


  21. HORIE M, Saito A, Ohshima M, Suzuki HI, et al
    YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Cancer Sci. 2016 Sep 14. doi: 10.1111/cas.13078.
    PubMed     Text format     Abstract available


  22. ZHANG P, Ma Y, Lv C, Huang M, et al
    The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy.
    Cancer Sci. 2016 Sep 1. doi: 10.1111/cas.13072.
    PubMed     Text format     Abstract available


  23. SUNADA S, Kanai H, Lee Y, Yasuda T, et al
    Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
    Cancer Sci. 2016;107:1250-5.
    PubMed     Text format     Abstract available


  24. ABE S, Kaneko MK, Tsuchihashi Y, Izumi T, et al
    Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Cancer Sci. 2016;107:1198-205.
    PubMed     Text format     Abstract available


    August 2016
  25. OHIRA T, Sakai K, Matsubayashi J, Kajiwara N, et al
    Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
    Cancer Sci. 2016 Aug 30. doi: 10.1111/cas.13068.
    PubMed     Text format     Abstract available


  26. WANG XZ, Cheng Y, Wang KL, Liu R, et al
    Peperomin E reactivates silenced tumor suppressor genes in lung cancer cells via inhibition of DNA methyltransferase.
    Cancer Sci. 2016 Aug 8. doi: 10.1111/cas.13029.
    PubMed     Text format     Abstract available


  27. FUJIWARA Y, Hamada A, Mizugaki H, Aikawa H, et al
    Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.
    Cancer Sci. 2016;107:1117-23.
    PubMed     Text format     Abstract available


    July 2016
  28. SUZUI M, Futakuchi M, Fukamachi K, Numano T, et al
    Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors.
    Cancer Sci. 2016;107:924-35.
    PubMed     Text format     Abstract available


    June 2016
  29. KOBAYASHI Y, Mitsudomi T
    Not all EGFR mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
    Cancer Sci. 2016 Jun 20. doi: 10.1111/cas.12996.
    PubMed     Text format     Abstract available


  30. SAITO M, Shiraishi K, Kunitoh H, Takenoshita S, et al
    Gene aberrations for precision medicine against lung adenocarcinoma.
    Cancer Sci. 2016;107:713-20.
    PubMed     Text format     Abstract available


    May 2016
  31. KAWAMURA T, Kenmotsu H, Taira T, Omori S, et al
    Rebiopsy for Patients with Non-Small-Cell Lung Cancer after Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Failure.
    Cancer Sci. 2016 May 4. doi: 10.1111/cas.12963.
    PubMed     Text format     Abstract available


    April 2016
  32. TAKASHINA T, Kinoshita I, Kikuchi J, Shimizu Y, et al
    Combined inhibition of EZH2 and HDACs as a potential epigenetic therapy for non-small cell lung cancer cells.
    Cancer Sci. 2016 Apr 26. doi: 10.1111/cas.12957.
    PubMed     Text format     Abstract available


  33. HARADA H, Fuji H, Ono A, Kenmotsu H, et al
    Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer.
    Cancer Sci. 2016 Apr 25. doi: 10.1111/cas.12955.
    PubMed     Text format     Abstract available


  34. PAISIE CA, Schrock MS, Karras JR, Zhang J, et al
    Exome-wide single-base substitutions in tissues and derived cell lines of the constitutive Fhit knockout mouse.
    Cancer Sci. 2016;107:528-35.
    PubMed     Text format     Abstract available


  35. GUO Z, Cao M, You A, Gao J, et al
    Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
    Cancer Sci. 2016;107:507-13.
    PubMed     Text format     Abstract available


    March 2016
  36. ZHANG F, Duan S, Tsai Y, Keng P, et al
    Cisplatin treatment increases stemness via up-regulation of hypoxia inducible factors by IL-6 in non-small cell lung cancer.
    Cancer Sci. 2016 Mar 24. doi: 10.1111/cas.12937.
    PubMed     Text format     Abstract available


  37. TAKAOKA S, Kamioka Y, Takakura K, Baba A, et al
    Live imaging of TAK1 activation in Lewis lung carcinoma 3LL cells implanted into syngeneic mice and treated with polyI:C.
    Cancer Sci. 2016 Mar 2. doi: 10.1111/cas.12923.
    PubMed     Text format     Abstract available


  38. PARK SY, Korm S, Chung HJ, Choi SJ, et al
    RAP80 regulates epithelial-mesenchymal transition related with metastasis and malignancy of cancer.
    Cancer Sci. 2016;107:267-73.
    PubMed     Text format     Abstract available


  39. SAWADA T, Watanabe M, Fujimura Y, Yagishita S, et al
    Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
    Cancer Sci. 2016;107:307-14.
    PubMed     Text format     Abstract available


  40. UCHIDA J, Imamura F, Kukita Y, Oba S, et al
    Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Cancer Sci. 2016;107:353-8.
    PubMed     Text format     Abstract available


    February 2016
  41. MIZUUCHI H, Suda K, Murakami I, Sakai K, et al
    Oncogene swap as a novel mechanism of acquired resistance to EGFR-tyrosine kinase inhibitor in lung cancer.
    Cancer Sci. 2016 Feb 4. doi: 10.1111/cas.12905.
    PubMed     Text format     Abstract available


  42. YAMANO S, Gi M, Tago Y, Doi K, et al
    Role of deltaNp63(pos)CD44v(pos) cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous cell carcinomas.
    Cancer Sci. 2016;107:123-32.
    PubMed     Text format     Abstract available


  43. IDA L, Yamaguchi T, Yanagisawa K, Kajino T, et al
    Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
    Cancer Sci. 2016;107:155-61.
    PubMed     Text format     Abstract available


    January 2016
  44. MISUMI K, Sun J, Kinomura A, Miyata Y, et al
    Enhanced gefitinib-induced repression of the EGFR pathway by ATM kinase inhibition in non-small cell lung cancer cells.
    Cancer Sci. 2016 Jan 30. doi: 10.1111/cas.12899.
    PubMed     Text format     Abstract available


  45. OTA M, Mochizuki S, Shimoda M, Abe H, et al
    ADAM23 is down-regulated in side population and suppresses lung metastasis of lung carcinoma cells.
    Cancer Sci. 2016 Jan 22. doi: 10.1111/cas.12895.
    PubMed     Text format     Abstract available


  46. SAITO Y, Nagae G, Motoi N, Miyauchi E, et al
    Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma.
    Cancer Sci. 2016 Jan 7. doi: 10.1111/cas.12876.
    PubMed     Text format     Abstract available


  47. SEKINE I, Sumi M, Satouchi M, Tsujino K, et al
    Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer.
    Cancer Sci. 2016 Jan 7. doi: 10.1111/cas.12875.
    PubMed     Text format     Abstract available


  48. SUZAWA K, Toyooka S, Sakaguchi M, Morita M, et al
    Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Cancer Sci. 2016;107:45-52.
    PubMed     Text format     Abstract available


    November 2015
  49. SUEOKA-ARAGANE N, Katakami N, Satouchi M, Yokota S, et al
    Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.
    Cancer Sci. 2015 Nov 17. doi: 10.1111/cas.12847.
    PubMed     Text format     Abstract available


    October 2015
  50. WANG Z, Luo Z, Zhou L, Li X, et al
    DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating beta-catenin signaling pathway.
    Cancer Sci. 2015;106:1303-12.
    PubMed     Text format     Abstract available


  51. MINAMI D, Takigawa N, Kato Y, Kudo K, et al
    Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
    Cancer Sci. 2015;106:1296-302.
    PubMed     Text format     Abstract available


    September 2015
  52. DING M, Li R, He R, Wang X, et al
    p53 activated by AND gate genetic circuit under radiation and hypoxia for targeted cancer gene therapy.
    Cancer Sci. 2015;106:1163-73.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: